Literature DB >> 31373247

For CLL cells, there's no place like home.

Benjamin L Lampson1, Jennifer R Brown1.   

Abstract

Entities:  

Year:  2019        PMID： 31373247      PMCID： PMC6928423          DOI： 10.1080/10428194.2019.1646910

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  19 in total

1.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia.

Authors:  Andrea Bürkle; Matthias Niedermeier; Annette Schmitt-Gräff; William G Wierda; Michael J Keating; Jan A Burger
Journal:  Blood       Date:  2007-07-25       Impact factor: 22.113

3.  Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia.

Authors:  Jan A Burger; Mariela Sivina; Nitin Jain; Ekaterina Kim; Tapan Kadia; Zeev Estrov; Graciela M Nogueras-Gonzalez; Xuelin Huang; Jeffrey Jorgensen; Jianling Li; Mei Cheng; Fong Clow; Maro Ohanian; Michael Andreeff; Thomas Mathew; Philip Thompson; Hagop Kantarjian; Susan O'Brien; William G Wierda; Alessandra Ferrajoli; Michael J Keating
Journal:  Blood       Date:  2018-12-07       Impact factor: 22.113

4.  Phase I Trial of the Pan-PI3K Inhibitor Pilaralisib (SAR245408/XL147) in Patients with Chronic Lymphocytic Leukemia (CLL) or Relapsed/Refractory Lymphoma.

Authors:  Jennifer R Brown; Matthew S Davids; Jordi Rodon; Pau Abrisqueta; Siddha N Kasar; Joanne Lager; Jason Jiang; Coumaran Egile; Farrukh T Awan
Journal:  Clin Cancer Res       Date:  2015-04-03       Impact factor: 12.531

5.  Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study.

Authors:  M Itälä; C H Geisler; E Kimby; E Juvonen; G Tjonnfjord; K Karlsson; K Remes
Journal:  Eur J Haematol       Date:  2002-09       Impact factor: 2.997

6.  Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity.

Authors:  J C Byrd; T Murphy; R S Howard; M S Lucas; A Goodrich; K Park; M Pearson; J K Waselenko; G Ling; M R Grever; A J Grillo-Lopez; J Rosenberg; L Kunkel; I W Flinn
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

7.  Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.

Authors:  J A Burger; M Burger; T J Kipps
Journal:  Blood       Date:  1999-12-01       Impact factor: 22.113

8.  A multicenter phase 1 study of plerixafor and rituximab in patients with chronic lymphocytic leukemia.

Authors:  Leslie A Andritsos; John C Byrd; Peter Cheverton; Jingyang Wu; Mariela Sivina; Thomas J Kipps; Jan A Burger
Journal:  Leuk Lymphoma       Date:  2019-07-27

9.  Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.

Authors:  Jennifer R Brown; Mehdi Hamadani; John Hayslip; Ann Janssens; Nina Wagner-Johnston; Oliver Ottmann; Jon Arnason; Hervé Tilly; Michael Millenson; Fritz Offner; Nashat Y Gabrail; Siddhartha Ganguly; Sikander Ailawadhi; Siddha Kasar; Arnon P Kater; Jeanette K Doorduijn; Lei Gao; Joanne J Lager; Bin Wu; Coumaran Egile; Marie José Kersten
Journal:  Lancet Haematol       Date:  2018-03-14       Impact factor: 18.959

10.  BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia.

Authors:  S-S Chen; B Y Chang; S Chang; T Tong; S Ham; B Sherry; J A Burger; K R Rai; N Chiorazzi
Journal:  Leukemia       Date:  2015-11-09       Impact factor: 11.528
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.